Psychedelic Drug Company MindMed Applies For Nasdaq Up-Listing
The company is currently listed on Canada’s NEO exchange and has a market cap of $190 million. MindMed’s announcement comes just days after U.K.-based Compass Pathways, which has patented a synthetic form of psilocybin for use in treatment-resistant depression, went public on the Nasdaq. Compass’ IPO is perhaps a bellwether signaling that some Wall Street […]
Psychedelic Drug Company MindMed Applies For Nasdaq Up-Listing Read More »